Aeglea Bio Therapeutics Inc (NASDAQ:AGLE) CEO Anthony G. Quinn acquired 6,256 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The stock was bought at an average price of $6.76 per share, for a total transaction of $42,290.56. Following the acquisition, the chief executive officer now owns 277,152 shares of the company’s stock, valued at approximately $1,873,547.52. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Shares of AGLE traded down $0.39 during trading hours on Friday, hitting $6.48. The company had a trading volume of 91,546 shares, compared to its average volume of 182,536. The company has a market cap of $194.74 million, a P/E ratio of -3.04 and a beta of 0.89. Aeglea Bio Therapeutics Inc has a 52-week low of $6.31 and a 52-week high of $12.00.
Aeglea Bio Therapeutics (NASDAQ:AGLE) last released its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.59) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.55) by ($0.04). Analysts expect that Aeglea Bio Therapeutics Inc will post -2.19 earnings per share for the current year.
Several research analysts have recently commented on the company. JPMorgan Chase & Co. assumed coverage on Aeglea Bio Therapeutics in a report on Thursday, March 21st. They issued an “overweight” rating and a $14.00 price objective on the stock. ValuEngine downgraded Aeglea Bio Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, March 9th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $14.67.
COPYRIGHT VIOLATION NOTICE: “Aeglea Bio Therapeutics Inc (AGLE) CEO Anthony G. Quinn Acquires 6,256 Shares” was first reported by Ticker Report and is the sole property of of Ticker Report. If you are viewing this news story on another domain, it was illegally copied and reposted in violation of U.S. and international copyright law. The legal version of this news story can be accessed at https://www.tickerreport.com/banking-finance/4344749/aeglea-bio-therapeutics-inc-agle-ceo-anthony-g-quinn-acquires-6256-shares.html.
Aeglea Bio Therapeutics Company Profile
Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers.
Read More: Is the QQQ ETF safe?
Receive News & Ratings for Aeglea Bio Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeglea Bio Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.